Estrogen and insulin/IGF-1 cooperatively stimulate cell cycle progression in MCF-7 breast cancer cells through differential regulation of c-Myc and cyclin D1

被引:104
作者
Mawson, A
Lai, A
Carroll, JS
Sergio, CM
Mitchell, CJ
Sarcevic, B
机构
[1] Garvan Inst Med Res, Canc Res Program, Darlinghurst, NSW 2010, Australia
[2] Johnson & Johnson Res Labs, Eveleigh, NSW 1430, Australia
[3] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA
[4] Harvard Univ, Sch Med, Boston, MA 02115 USA
[5] Garvan Inst Med Res, Diabet & Obes Res Program, Darlinghurst, NSW 2010, Australia
基金
英国医学研究理事会;
关键词
estrogen; insulin; IGF-1; c-Myc; cyclin D1;
D O I
10.1016/j.mce.2004.08.002
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Estrogen and insulin/insulin-like growth factor-I (IGF-I) are major mitogens for breast epithelial cells and when co-administered, synergistically induce G(1)-S phase cell cycle progression. We investigated this cooperativity by evaluating if the key cell cycle regulators. c-Myc and cyclin D1, represent points of convergence in the action of these mitogens in MCF-7 breast cancer cells. These studies demonstrated that estrogen significantly increased both c-Myc and cyclin D1 protein, while insulin predominantly increased cyclin D1 levels. This cumulative increase in c-Myc and cyclin D1 contributes to the cooperativity of these mitogens, since ectopic expression of c-Myc or cyclin D1 cooperates with either the estrogen Or insulin signaling pathways to increase cell cycle progression. Inhibition of the MAPK or PI3-kinase pathway significantly reduced c-Myc and cyclin D1 protein levels and cell cycle progression. Ectopic expression of cyclin D1 partially overcame this inhibition, while ectopic expression of c-Myc partially overcame MAPK but not PI3-kinase inhibition. Therefore, estrogen and insulin/IGF-1 differentially regulate c-Myc and cyclin D1 to cooperatively stimulate breast cancer cell proliferation. (C) 2004 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:161 / 173
页数:13
相关论文
共 63 条
[1]   Mechanism of activation of protein kinase B by insulin and IGF-1 [J].
Alessi, DR ;
Andjelkovic, M ;
Caudwell, B ;
Cron, P ;
Morrice, N ;
Cohen, P ;
Hemmings, BA .
EMBO JOURNAL, 1996, 15 (23) :6541-6551
[2]   Sustained MAP kinase activation is required for the expression of cyclin D1, p21Cip1 and a subset of AP-1 proteins in CCL39 cells [J].
Balmanno, K ;
Cook, SJ .
ONCOGENE, 1999, 18 (20) :3085-3097
[3]   PARALLEL SIGNAL-PROCESSING AMONG MAMMALIAN MAPKS [J].
CANO, E ;
MAHADEVAN, LC .
TRENDS IN BIOCHEMICAL SCIENCES, 1995, 20 (03) :117-122
[4]  
Carroll JS, 2002, CANCER RES, V62, P3126
[5]   PI3-kinase in concert with Src promotes the S-phase entry of oestradiol-stimulated MCF-7 cells [J].
Castoria, G ;
Migliaccio, A ;
Bilancio, A ;
Di Domenico, M ;
de Falco, A ;
Lombardi, M ;
Fiorentino, R ;
Varricchio, L ;
Barone, MV ;
Auricchio, F .
EMBO JOURNAL, 2001, 20 (21) :6050-6059
[6]   Non-transcriptional action of oestradiol and progestin triggers DNA synthesis [J].
Castoria, G ;
Barone, MV ;
Di Domenico, M ;
Bilancio, A ;
Ametrano, D ;
Migliaccio, A ;
Auricchio, F .
EMBO JOURNAL, 1999, 18 (09) :2500-2510
[7]  
Chen B, 2004, T NONFERR METAL SOC, V14, P25
[8]   Relationship between estrogen levels, use of hormone replacement therapy, and breast cancer [J].
Colditz, GA .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1998, 90 (11) :814-823
[9]   Estrogen receptor null mice: What have we learned and where will they lead us? [J].
Couse, JF ;
Korach, KS .
ENDOCRINE REVIEWS, 1999, 20 (03) :358-417
[10]   REGULATION OF HUMAN BREAST-CANCER BY SECRETED GROWTH-FACTORS [J].
CULLEN, KJ ;
YEE, D ;
BATES, SE ;
BRUNNER, N ;
CLARKE, R ;
DICKSON, RE ;
HUFF, KK ;
PAIK, S ;
ROSEN, N ;
VALVERIUS, E ;
ZUGMAIER, G ;
LIPPMAN, ME .
ACTA ONCOLOGICA, 1989, 28 (06) :835-839